background
largest
outbreak
middl
east
respiratori
syndrom
coronaviru
merscov
infect
outsid
middl
east
asia
necessit
rapid
expans
laboratori
conduct
merscov
molecular
test
korea
togeth
extern
qualiti
assess
eqa
evalu
assay
use
method
eqa
program
consist
two
phase
selfvalid
blind
assess
first
eqa
phase
vitro
transcrib
upstream
region
envelop
gene
upe
open
read
frame
orf
rna
use
concentr
test
panel
second
eqa
phase
consist
rna
extract
three
sampl
obtain
two
merscov
posit
patient
one
merscov
neg
patient
result
first
eqa
phase
result
particip
show
linear
relationship
threshold
cycl
ct
valu
rna
materi
logarithm
concentr
upe
gene
target
r
respect
mean
ct
valu
concentr
differ
depend
commerci
kit
use
assay
among
three
commonli
use
kit
powerchek
mer
realtim
pcr
kit
kogenebiotech
korea
show
lowest
ct
valu
concentr
upe
concentr
second
eqa
phase
result
particip
correct
test
sampl
conclus
eqa
survey
demonstr
merscov
molecular
test
perform
korea
outbreak
robust
capabl
howev
care
establish
valid
cutoff
valu
recommend
ensur
good
analyt
sensit
middl
east
respiratori
syndrom
coronaviru
merscov
novel
human
pathogen
associ
sever
respiratori
ill
first
detect
saudi
arabia
confirmatori
merscov
test
recommend
base
realtim
revers
transcriptasepcr
rrtpcr
two
differ
targetsan
upstream
region
envelop
gene
upe
firstlin
screen
region
within
open
read
frame
orf
sequenc
nucleocapsid
n
gene
rnadepend
rna
polymeras
rdrp
gene
confirm
first
case
merscov
infect
korea
identifi
recent
man
travel
middl
east
two
week
prior
diagnosi
subsequ
korean
infect
fourweek
period
contact
hospit
household
environ
largest
outbreak
merscov
infect
outsid
middl
east
asia
necessit
rapid
expans
laboratori
conduct
merscov
test
short
period
well
use
assay
approv
diagnost
purpos
therefor
urgent
extern
qualiti
assess
eqa
propos
order
assess
qualiti
assay
use
report
experi
eqa
carri
merscov
outbreak
owe
rapid
introduct
molecular
diagnost
merscov
eqa
program
consist
two
phase
first
phase
particip
perform
selfvalid
method
use
known
concentr
distribut
viral
materi
second
phase
particip
perform
blind
assess
use
unknown
concentr
distribut
viral
materi
inform
regard
merscov
eqa
sent
institut
member
korean
societi
laboratori
medicin
applic
receiv
via
korean
societi
laboratori
medicin
korean
hospit
associ
total
number
laboratori
particip
two
phase
eqa
june
juli
respect
first
eqa
phase
vitro
transcrib
upe
rna
provid
univers
bonn
medic
center
germani
use
concentr
test
panel
second
eqa
phase
consist
rna
extract
three
sampl
sampl
b
c
two
merscovposit
patient
repres
high
posit
low
posit
level
one
patient
merscovneg
materi
assay
use
rrtpcr
test
merscov
rna
previous
describ
briefli
reaction
prepar
rna
primer
probe
enzym
mix
rtpcr
buffer
revers
transcript
done
min
pcr
cycl
condit
min
follow
cycl
sec
sec
eqa
sampl
ship
frozen
dri
ice
specialist
courier
follow
inform
collect
particip
assay
kit
platform
use
cutoff
ct
valu
result
materi
comparison
threshold
cycl
ct
valu
assay
kit
platform
perform
use
mannwhitney
test
use
medcalc
softwar
packag
medcalc
softwar
ostend
belgium
p
valu
consid
statist
signific
first
eqa
materi
distribut
laboratori
result
return
respons
rate
second
eqa
materi
distribut
laboratori
result
return
respons
rate
particip
use
commerci
rrtpcr
kit
powerchek
mer
realtim
pcr
kit
kogenebiotech
daejon
korea
common
follow
diaplexq
mer
viru
detect
kit
solgent
seoul
korea
accupow
merscov
realtim
rtpcr
kit
bioneer
daejon
korea
tabl
two
particip
first
phase
one
particip
second
phase
eqa
use
inhous
rrtpcr
method
particip
report
upe
result
semiquantit
manner
ct
valu
differ
cutoff
valu
employ
depend
kit
use
accupow
powerchek
diaplexq
respect
first
phase
eqa
particip
perform
selfvalid
protocol
particip
laboratori
use
variou
concentr
exclud
valid
result
conveni
interpret
thu
use
selfvalid
result
final
analysi
result
first
phase
eqa
summar
tabl
ever
case
signific
p
respect
ct
valu
rna
linear
relationship
logarithm
concentr
upe
boxplot
fig
r
respect
linear
relationship
also
observ
two
common
commerci
kit
powerchek
diaplexq
r
upe
r
respect
among
result
obtain
use
powerchek
kit
ct
valu
abi
system
appli
biosystem
forster
citi
ca
usa
show
tendenc
lower
biorad
biorad
carlsbad
ca
usa
across
concentr
statist
signific
tabl
addit
ct
valu
upe
mostli
lower
also
statist
signific
tabl
second
phase
eqa
panel
result
particip
correct
three
sampl
test
tabl
differ
mean
ct
valu
commerci
kit
second
eqa
phase
similar
first
eqa
phase
powerchek
kit
show
lowest
ct
valu
upe
differ
statist
signific
except
sampl
sampl
p
p
upe
respect
sampl
b
p
p
upe
respect
analyz
effect
realtim
platform
studi
result
among
result
obtain
use
powerchek
kit
ct
valu
abi
system
found
lower
biorad
two
merscovposit
sampl
tabl
differ
statist
signific
except
sampl
b
ct
valu
upe
also
found
lower
two
merscovposit
sampl
second
eqa
phase
statist
signific
p
respect
recent
intern
eqa
molecular
diagnost
merscov
conduct
across
laboratori
six
contin
publish
report
eqa
merscov
test
best
knowledg
studi
first
eqa
merscov
test
conduct
affect
region
outbreak
worldwid
korean
outbreak
largest
outbreak
merscov
infect
outsid
middl
east
asia
demand
rapid
expans
merscov
test
laboratori
unapprov
commerci
kit
vitro
diagnost
use
introduc
clinic
laboratori
without
formal
valid
diagnost
test
rais
issu
qualiti
studi
laboratori
particip
eqa
two
phase
show
overal
good
result
nevertheless
eqa
scheme
limit
first
scheme
could
reflect
import
practic
step
sampl
prepar
nucleic
acid
extract
vitro
transcrib
rna
extract
rna
use
eqa
second
first
phase
analyt
valid
set
use
particip
dilut
scheme
limit
repeat
test
obtain
final
result
therefor
laboratori
provid
result
concentr
analyz
studi
posit
result
lower
concentr
could
variou
test
repeat
mean
result
eqa
phase
may
suitabl
interlaboratori
comparison
third
second
phase
assess
compris
three
sampl
includ
one
strong
posit
weak
posit
includ
divers
concentr
especi
lower
end
analyt
sensit
rrtpcr
lastli
coronavirus
includ
assess
analyt
specif
diagnost
assay
survey
particip
use
commerci
rrtpcr
kit
result
show
significantli
differ
ct
valu
could
produc
depend
kit
use
though
kit
semiquantit
purpos
differ
ct
valu
correl
differ
analyt
sensit
larg
differ
ct
valu
materi
may
influenc
analyt
sensit
kit
therefor
cutoff
valu
care
valid
method
order
optim
sensit
detect
merscov
clinic
set
addit
studi
demonstr
ct
valu
might
differ
depend
platform
use
perform
realtim
pcr
even
use
commerci
kit
therefor
platform
well
kit
consid
establish
valid
cutoff
valu
kit
known
analyt
sensit
merscov
rtpcr
depend
target
gene
test
assay
lower
sensit
compar
upe
assay
survey
particip
report
upe
result
assay
gave
compar
result
signific
differ
observ
summari
eqa
survey
demonstr
merscov
molecular
test
carri
korea
outbreak
base
robust
method
howev
care
establish
valid
cutoff
valu
recommend
ensur
analyt
sensit
